Viva Biotech HoldingsFRA:VB0 +2.59%47 ROE % is 4.98% as of Dec. 2025, which is 25% below its 10-year median of 6.68. GuruFocus rates FRA:VB0 with a GF Score™ of 47/100 and a GF Value™ of €0.08 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,251 Biotechnology companies, Viva Biotech Holdings ranks better than 84.33% on this metric.
The historical rank and industry rank for Viva Biotech Holdings's ROE % or its related term are showing as below:
FRA:VB0'
s ROE % Range Over the Past 10 Years
Min: -14.26 Med: 6.68 Max: 67.74
Current: 5.69
During the past 10 years, Viva Biotech Holdings's highest ROE % was 67.74%. The lowest was -14.26%. And the median was 6.68%.
FRA:VB0's ROE % is ranked better than 84.33% of 1251
companies
in the Biotechnology industry
Industry Median: -38.11
vs FRA:VB0: 5.69
Viva Biotech Holdings (FRA:VB0) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Viva Biotech Holdings's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viva Biotech Holdings ROE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Viva Biotech Holdings's ROE % distribution charts can be found below:
* The bar in red indicates where Viva Biotech Holdings's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
ROE % is displayed in the 30-year financial page.
Viva Biotech Holdings (FRA:VB0) has a ROE % of 4.98% as of Dec. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Viva Biotech Holdings and its competitors. This is 25% below median its historical median of 6.68. According to the industry distribution chart, Viva Biotech Holdings ranks #196 out of 1251 companies in the Biotechnology industry, placing it in the top 15.7%.
Is Viva Biotech Holdings' ROE % too high?
Viva Biotech Holdings' current ROE % of 4.98% is 25% below median its 10-year median of 6.68. Based on the distribution chart, Viva Biotech Holdings ranks #196 out of 1251 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Viva Biotech Holdings has a GF Score™ of 47/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Viva Biotech Holdings' ROE % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Viva Biotech Holdings ranks #196 out of 1251 companies for ROE %. This places Viva Biotech Holdings in the top 16% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Biotechnology company?
A good ROE % depends on the Biotechnology industry context. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Viva Biotech Holdings and its competitors. Viva Biotech Holdings's current ROE % is 4.98%, which is 25% below median its own 10-year median of 6.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viva Biotech Holdings stock overvalued right now?
Based on GuruFocus' analysis, Viva Biotech Holdings (FRA:VB0) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.08, compared to a current price of €0.12 — trading 48.8% above its estimated fair value. The current ROE % is 4.98%, which is 25% below median its 10-year median of 6.68. Viva Biotech Holdings' overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Viva Biotech Holdings (FRA:VB0), the current ROE % is 4.98% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Viva Biotech Holdings (FRA:VB0) Overvalued in 2026?
Based on GuruFocus' analysis, Viva Biotech Holdings stock appears to be overvalued.
The current stock price of €0.12 is trading 48.8% above its estimated GF Value™ of €0.08.
GuruFocus considers Viva Biotech Holdings to be Significantly Overvalued.
Key valuation signals for FRA:VB0:
ROE %: 4.98% (25% below median its 10-year median of 6.68)
GF Value™: €0.08 vs. price of €0.12 (48.8% above fair value)
No single metric tells the full story. See the FRA:VB0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Viva Biotech Holdings is engaged in providing the structure-based drug discovery services to biotechnology and pharmaceutical customers for their pre-clinical stage drug development. The company operates in three reportable segments, Drug Discovery Services providing structure-based drug discovery services to biotechnology and pharmaceutical customers for their pre-clinical stage drug development; Contract Development Manufacture Organisation providing contract development and manufacturing services for small molecule APIs and intermediates and trading of APIs, intermediates and formulations; and commercialisation services; and Viva BioInnovator making strategic investments in biotechnology startup companies.
47GF Score
Get the complete analysis for FRA:VB0
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:VB0 has been successfully added to your 
